OZEM Roundhill Investments - GLP-1 & Weight Loss ETF
Quote as of Aug 26, 2026 20:00 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 34.23 | Day Range | 34.02 – 34.41 |
| 52-Week Range | 25.66 – 37.15 | Volume | 8.40K |
| Avg Volume | 22.11K | AUM | $65.4M (Aug 26, 2026) |
| Expense Ratio | 0.59% | Yield (TTM) | 1.20% |
| NAV | 33.90 | Premium/Discount | +0.79% indicative |
| Inception | May 21, 2024 | Holdings | 29 |
| Issuer | Roundhill Investments | Exchange | NASDAQ |
| Category | Healthcare | Index Tracked | Not stated in source data |
| CUSIP | 77926X882 | ISIN | US77926X8829 |
| Management | Not stated in source data | ||
About this ETF
Roundhill considers weight loss medications, particularly GLP-1 agonists, to be among the most groundbreaking innovations currently reshaping the global pharmaceutical landscape. This conviction underpins the Roundhill GLP-1 & Weight Loss ETF (OZEM), which is distinguished as the world's inaugural ETF exclusively focused on the GLP-1 and broader weight management sector. Notably, OZEM employs an active management approach.
Description from the fund data provider · profile as of Aug 26, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +5.62% | +10.25% | +0.19% | +0.31% | +34.95% | — | — | — | +14.21% |
| Total return | +5.61% | +10.23% | +0.18% | +0.29% | +36.55% | — | — | — | +14.91% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Aug 25, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.59% | Annual cost of a $10,000 investment | $59.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Aug 22, 2026 — portfolio reporting date from the data provider; holdings are not live positions. 27 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | Eli Lilly & Co | LLY | 12.71% | 6.61K | $8.3M |
| 2 | Novo Nordisk A/S | NVO | 12.11% | 168.98K | $7.9M |
| 3 | Pfizer Inc | PFE | 7.13% | 165.70K | $4.7M |
| 4 | CSPC Pharmaceutical Group Ltd | 1093.HK | 6.70% | 3.73M | $4.4M |
| 5 | Viking Therapeutics Inc | VKTX | 4.87% | 93.82K | $3.2M |
| 6 | Kailera Therapeutics Inc | KLRA | 4.64% | 176.24K | $3.0M |
| 7 | Amgen Inc | AMGN | 4.47% | 6.63K | $2.9M |
| 8 | Zealand Pharma A/S | ZEAL.CO | 4.25% | 55.31K | $2.8M |
| 9 | Chugai Pharmaceutical Co Ltd | 4519.T | 4.09% | 60.50K | $2.7M |
| 10 | Hanmi Pharm Co Ltd | 128940.KS | 3.91% | 8.51K | $2.6M |
| 11 | Ascletis Pharma Inc | 1672.HK | 3.81% | 1.94M | $2.5M |
| 12 | Roche Holding AG | ROP.SW | 3.28% | 4.57K | $2.1M |
| 13 | MBX Biosciences Inc | MBX | 3.22% | 31.68K | $2.1M |
| 14 | AstraZeneca PLC | AZN | 3.21% | 12.62K | $2.1M |
| 15 | Innovent Biologics Inc | 1801.HK | 2.90% | 145.00K | $1.9M |
| 16 | Hansoh Pharmaceutical Group Co Ltd | 3692.HK | 2.72% | 420.00K | $1.8M |
| 17 | United Laboratories International Holdings… | 3933.HK | 2.68% | 1.52M | $1.8M |
| 18 | Structure Therapeutics Inc | GPCR | 2.68% | 35.56K | $1.7M |
| 19 | Gubra A/S | GUBRA.CO | 2.23% | 23.80K | $1.5M |
| 20 | Jiangsu Hengrui Pharmaceuticals Co Ltd | 1276.HK | 2.05% | 218.00K | $1.3M |
| 21 | Gilead Sciences Inc | GILD | 1.92% | 8.57K | $1.3M |
| 22 | Rhythm Pharmaceuticals Inc | RYTM | 1.55% | 9.19K | $1.0M |
| 23 | Shionogi & Co Ltd | 4507.T | 1.25% | 44.50K | $817.1K |
| 24 | First American Government Obligations Fund… | FGXXX | 0.83% | 542.28K | $542.3K |
| 25 | Wave Life Sciences Inc | WVE | 0.75% | 92.94K | $491.6K |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 1.20% | Paid (last 12 months) | $0.4099 |
| Frequency | Irregular | SEC yield | Not provided by our data source — see the issuer page |
| Last ex-date | Dec 30, 2025 | Last payment | $0.4099 (Dec 31, 2025) |
| Growth 1Y | — | Growth 3Y / 5Y (ann.) | — / — |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Dec 30, 2025 | Dec 30, 2025 | Dec 31, 2025 | $0.4099 |
| Dec 30, 2024 | Dec 30, 2024 | Dec 31, 2024 | $0.0531 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 23.07% / — | Sharpe 1Y / 3Y | 1.59 / — |
| Max drawdown 1Y / 3Y | -19.51% / — | Sortino 1Y | 2.50 |
| Beta vs S&P 500 (3Y) | 0.73 | Correlation vs S&P 500 (1Y) | 0.398 |
| Downside deviation 1Y | 14.65% | Risk-free rate used | 3.72% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Aug 26, 2026. Formulas →
Liquidity
| Volume today | 8.40K | Average volume | 22.11K |
| AUM | $65.4M | Premium/Discount | +0.79% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV — an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | $180.2K | +0.28% | $65.2M → $65.4M |
| 1 Week | $1.5M | +2.35% | $63.7M → $65.4M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source — review them before investing.
Latest News for OZEM
No articles mention this fund directly in the last 7 days — showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.